Abstract
Background: Progressive multiple sclerosis (MS) presents a persistent translational challenge: credible biological activity has often failed to produce confirmed disability benefit. Contemporary trials offer contrasting tests of therapeutic mechanism, population selection, and outcome measurement, with direct implications for research participation in the Gulf Cooperation Council (GCC). Methods: This structured comparative review combined reproducible PubMed retrieval with purposive selection of 46 programme entries and targeted verification of publications, trial records, and regulatory assessments through 6 September 2026. Primary results, secondary findings, and interpretive constraints were extracted separately. A regional search informed a protocol-linked GCC dataset. Heterogeneous comparisons were synthesized without pooling; independent comprehensive screening and formal outcome-level appraisal were not completed. Results: ORATORIO, EXPAND, and HERCULES established disability benefit in defined populations. Contrasting findings from PERSEUS, GAVOTTE, and MS-STAT2 limited extrapolation across phenotypes, exposure strategies, and imaging outcomes. ORATORIO-HAND extended positive evidence to broader primary progressive MS eligibility, whereas FENtrepid reported active-comparator noninferiority. Participant-level analyses supported the clinical relevance of walking and hand-function deterioration, while treatment-effect detection remained dependent on component contributions. Regulatory assessments demonstrated that efficacy, population-specific certainty, and serious liver injury jointly determine therapeutic translation. Regional sources documented research infrastructure but did not establish protocol-specific recruitment capacity. The synthesis generated four testable hypotheses and a 40-field GCC dictionary with an eligibility-critical core. Conclusions: Progressive-MS development requires evidence connecting relevant target engagement, a clinically characterized population, meaningful functional preservation, and acceptable risk. This framework converts contrasting trial results into prospective design questions and gives GCC centres a practical basis for testing recruitment readiness and the applicability of international evidence.